2020-12-03 08:22 Overview Target Indication Mechanism of Action Status Drug Name CD3xCD20 bsAb Description Anti-CD3/CD20 bispecific antibody (CD3xCD20 bsAb) is able to bring T cells to tumor microenvironment. Experiments demonstrated that low-toxic CD3xCD20 bsAb has a strong T cell activation capability to kill cancer cells: in vitro experiments showed that CD3xCD20 bsAb can effectively kill Rituximab-resistant tumor &hellip
Вы можете показать это желание на своем сайте, в блоге, в форуме и т.д., скопировав и вставив туда этот HTML-код.
